SCHEMBL14723650

SCHEMBL14723650

CCOc1cccc2c(C(=O)C(C)C)nc(Cl)cc12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
TSHR P16473 1/20 0.38
ALDH1A1 P00352 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
POLB P06746 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TTR P02766 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
KDM4E B2RXH2 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
GLA P06280 1/20 0.35
ADRB3 P13945 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12798518 0.86 ALDH1A1 (0.44) L3MBTL1ALDH1A1POLBSMN1; SMN2KDM4E
SCHEMBL753231 0.86 DYRK1A (0.43) L3MBTL1TSHRALDH1A1RXFP1POLB
SCHEMBL14723766 0.86 ALDH1A1 (0.40) L3MBTL1TSHRALDH1A1RXFP1POLB
SCHEMBL13389771 0.85 TSHR (0.39) L3MBTL1TSHRALDH1A1RXFP1POLB
SCHEMBL13379438 0.82 TSHR (0.38) L3MBTL1TSHRALDH1A1RXFP1POLB
SCHEMBL305742 0.77 ALDH1A1 (0.44) L3MBTL1TSHRALDH1A1RXFP1POLB
SCHEMBL18730881 0.76 ADORA2B (0.46) L3MBTL1ALDH1A1POLBKDM4E
SCHEMBL12798535 0.74 KDM4E (0.40) TSHRALDH1A1CYP1A2CYP2C19KDM4E
SCHEMBL13388261 0.73 ALDH1A1 (0.44) L3MBTL1ALDH1A1POLBKDM4E
SCHEMBL756465 0.71 PKM (0.40) L3MBTL1ALDH1A1POLBSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383094-B2 inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed